Evgen reported full-year results to 31 March that were c.£0.3m better than expected, with an adjusted net loss of £2.7m that resulted in year-end cash of £4.1m, which provides a cash runway into H2 FY 2022. Evgen is in the midst of completing both the CMC and extended toxicology packages for a tablet formulation that will enable future dosing of more than 28 days; not just for use in a placebo-controlled Phase II metastatic breast cancer trial, which is in the final phase of
15 Jun 2020
Evgen Pharma - FY 2020 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evgen Pharma - FY 2020 results
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.42m
- Published:
15 Jun 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
10
Evgen reported full-year results to 31 March that were c.£0.3m better than expected, with an adjusted net loss of £2.7m that resulted in year-end cash of £4.1m, which provides a cash runway into H2 FY 2022. Evgen is in the midst of completing both the CMC and extended toxicology packages for a tablet formulation that will enable future dosing of more than 28 days; not just for use in a placebo-controlled Phase II metastatic breast cancer trial, which is in the final phase of